Oxycodegol
Top View
![]() | |
Names | |
---|---|
IUPAC name (4R,4aS,7S,7aR,12bS)-9-methoxy-7-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol | |
Other names Loxicodegol; NKTR-181 | |
Identifiers | |
3D model (JSmol) | |
ChemSpider | |
DrugBank | |
KEGG | |
PubChem CID | |
UNII | |
| |
| |
Properties | |
C31H49NO10 | |
Molar mass | 595.730 g·mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Oxycodegol (also known as loxicodegol and NKTR-181) is an experimental μ-opioid receptor agonist for the treatment of pain. It has had success for back pain as an alternative to traditional opioids, which have potential for abuse. It acts more slowly on the central nervous system, reducing risk for abuse and respiratory depression.
References
[edit]- ^ Advokat, Claire D.; Comaty, Joseph E.; Julien, Robert M. (2019). Julien's Primer of Drug Action: a comprehensive guide to the actions, uses, and side effects of psychoactive drugs. New York: Worth Publishers. p. 565. ISBN 978-1-319-20054-1.
- ^ "NKTR-181 (Oxycodegol) Oral Tablets for. Chronic Low Back Pain". Food and Drug Administration. Archived from the original on 24 December 2020.
- ^ Markman, John; Gudin, Jeffrey; Rauck, Richard; Argoff, Charles; Rowbotham, Matthew; Agaiby, Eva; Gimbel, Joseph; Katz, Nathaniel; Doberstein, Stephen K; Tagliaferri, Mary; Lu, Lin; Saddhanti, Suresh; Hale, Martin (June 2019). "SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain". PAIN. 160 (6): 1374–1382. doi:10.1097/j.pain.0000000000001517. PMC 6553961. PMID 30747908.